Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 14, 2026

India Data Center Market Investment Analysis & Growth Report 2026-2031: Mumbai, Navi Mumbai, Hyderabad, Chennai, and Pune Attract Major Investments from ST Telemedia, NTT DATA, and Equinix

View original at finance.yahoo.com
India Data Center Market Investment Analysis & Growth Report 2026-2031: Mumbai, Navi Mumbai, Hyderabad, Chennai, and Pune Attract Major Investments from ST Telemedia, NTT DATA, and Equinix Company Logo India's Data Center Market is valued at USD 9.79 billion in 2025 and expected to reach USD 21.03 billion by 2031, grow…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Sify Technologies has planned to implement liquid cooling system in other facilities in India, which will support approximately 130 kW/rack

    80% confidence

  • Power challenges are likely to be reduced due to government initiatives and data center operators adopting renewable energy and in-house grid systems

    80% confidence

  • India's Data Center Market is valued at USD 9.79 billion in 2025 and expected to reach USD 21.03 billion by 2031, growing at a CAGR of 13.59%

    80% confidence

  • Most data centers are expected to adopt liquid cooling system, which uses less water than traditional cooling system

    80% confidence

  • Mumbai, Navi Mumbai, Hyderabad, Chennai, Pune are the preferred locations in India for data center investments

    80% confidence

  • Water challenges are likely to emerge as a future challenge in the Indian data center market

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com